{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:50:26Z","timestamp":1790009426829,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Beijing Key Clinical Specialty Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The association between the use of angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer risk remains controversial. This study evaluated the association between the use of ACEIs and lung cancer risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Records from five databases were searched from inception to 26 January 2022. Clinical studies involving persons aged \u226518 years with at least one year of follow-up and reporting adverse events, including lung cancer, were recorded with separate outcome reports supplied for the ACEIs and control groups. Data were extracted independently by three authors and pooled using a random-effects model. The primary outcome was lung cancer development. Odds ratios (ORs) with 95% confidence intervals (CIs) and lung cancer-related morbidity were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 2400 records screened, 13,061,226 patients were included from seven cohort studies and four case\u2013control studies. Pooled results showed that ACEIs use was linked to increased lung cancer risk (OR 1.19, 95% CI 1.05\u20131.36; <jats:italic>P<\/jats:italic>\u2009=\u20090.008), with high heterogeneity (<jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200998%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ACEI usage is a greater risk factor for lung carcinogenesis than angiotensin receptor blocker use, especially in Asian patients. Further randomised controlled trials are needed to confirm the causal association between the use of ACEIs and lung cancer risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-02029-5","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T09:05:05Z","timestamp":1668675905000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"128","author":[{"given":"Zhenchao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taikang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-0677","authenticated-orcid":false,"given":"Ning","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"2029_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745\u201359.","journal-title":"Nat Rev Cancer"},{"key":"2029_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2165\/00003495-198325010-00002","volume":"25","author":"JA Romankiewicz","year":"1983","unstructured":"Romankiewicz JA, Brogden RN, Heel RC, Speight TM, Avery GS. Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs. 1983;25:6\u201340.","journal-title":"Drugs"},{"key":"2029_CR3","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.mayocp.2020.03.026","volume":"95","author":"F Sanchis-Gomar","year":"2020","unstructured":"Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin-converting enzyme inhibitors) in coronavirus disease 2019. Mayo Clin Proc. 2020;95:1222\u201330.","journal-title":"Mayo Clin Proc"},{"key":"2029_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","volume":"21","author":"M Regulski","year":"2015","unstructured":"Regulski M, Regulska K, Stanisz BJ, Murias M, Gieremek P, Wzgarda A, et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des. 2015;21:1764\u201375.","journal-title":"Curr Pharm Des"},{"key":"2029_CR5","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","volume":"332","author":"SE McDowell","year":"2006","unstructured":"McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332:1177\u201381.","journal-title":"BMJ"},{"key":"2029_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/crj.13143","volume":"14","author":"\u0130 Y\u0131lmaz","year":"2020","unstructured":"Y\u0131lmaz \u0130, T\u00fcrk M, Baran Ketencio\u011flu B, \u00c7etinkaya Z, Tutar N, Oymak FS, et al. The presence of underlying asthma should be investigated in patients diagnosed with ACE inhibitor induced cough. Clin Respir J. 2020;14:382\u20138.","journal-title":"Clin Respir J"},{"key":"2029_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/jhh.2009.21","volume":"23","author":"T Rosenthal","year":"2009","unstructured":"Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623\u201335.","journal-title":"J Hum Hypertens"},{"key":"2029_CR8","doi-asserted-by":"publisher","first-page":"663671","DOI":"10.3389\/fonc.2021.663671","volume":"11","author":"K Xu","year":"2021","unstructured":"Xu K, Han H, Luo Y, Ye H, Lin H, Ni L. The angiotensin-converting enzyme inhibitory state promotes the transformation of non-small cell lung cancer blood supply pattern toward vasculogenic mimicry formation. Front Oncol. 2021;11:663671.","journal-title":"Front Oncol"},{"key":"2029_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc. 2004;292:2217\u201325.","journal-title":"J Am Med Assoc"},{"key":"2029_CR10","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009;24:3694\u2013701.","journal-title":"Nephrol Dial Transpl"},{"key":"2029_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","volume":"128","author":"M Ravid","year":"1998","unstructured":"Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982\u20138.","journal-title":"Ann Intern Med"},{"key":"2029_CR12","doi-asserted-by":"publisher","first-page":"k4209","DOI":"10.1136\/bmj.k4209","volume":"363","author":"BM Hicks","year":"2018","unstructured":"Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209.","journal-title":"BMJ"},{"key":"2029_CR13","doi-asserted-by":"publisher","first-page":"e006687","DOI":"10.1161\/CIRCOUTCOMES.120.006687","volume":"14","author":"KB Kristensen","year":"2021","unstructured":"Kristensen KB, Hicks B, Azoulay L, Potteg\u00e5rd A. Use of ACE (angiotensin-converting enzyme) inhibitors and risk of lung cancer: a nationwide nested case-control study. Circ Cardiovasc Qual Outcomes. 2021;14:e006687.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2029_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/cancers12030747","volume":"12","author":"SY Lin","year":"2020","unstructured":"Lin SY, Lin CL, Lin CC, Hsu WH, Lin CD, Wang IK, et al. Association between angiotensin-converting enzyme inhibitors and lung cancer\u2014a nationwide, population-based, propensity score-matched cohort study. Cancers. 2020;12:747.","journal-title":"Cancers"},{"key":"2029_CR15","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-05-2489","volume":"12","author":"PJ Wysocki","year":"2006","unstructured":"Wysocki PJ, Kwiatkowska EP, Kazimierczak U, Suchorska W, Kowalczyk DW, Mackiewicz A. Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin Cancer Res. 2006;12:4095\u2013102.","journal-title":"Clin Cancer Res"},{"key":"2029_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<761::AID-IJC16>3.0.CO;2-1","volume":"81","author":"C Prontera","year":"1999","unstructured":"Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999;81:761\u20136.","journal-title":"Int J Cancer"},{"key":"2029_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","volume":"108","author":"I Sipahi","year":"2011","unstructured":"Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108:294\u2013301.","journal-title":"Am J Cardiol"},{"key":"2029_CR18","doi-asserted-by":"publisher","first-page":"e25714","DOI":"10.1097\/MD.0000000000025714","volume":"100","author":"M Batais","year":"2021","unstructured":"Batais M, Almigbal T, Alotaibi K, Alodhayani A, Alkhushail A, Altheaby A, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: a systematic review and meta-analysis. Medicine. 2021;100:e25714.","journal-title":"Medicine"},{"key":"2029_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00432-020-03445-x","volume":"147","author":"T Rachow","year":"2021","unstructured":"Rachow T, Schiffl H, Lang SM. Risk of lung cancer and renin-angiotensin blockade: a concise review. J Cancer Res Clin Oncol. 2021;147:195\u2013204.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2029_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97989-8","volume":"11","author":"SH Lee","year":"2021","unstructured":"Lee SH, Chun KJ, Park J, Kim J, Sung JD, Park RW, et al. Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea. Sci Rep. 2021;11:18576.","journal-title":"Sci Rep."},{"key":"2029_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336.","journal-title":"Lancet Oncol"},{"key":"2029_CR22","doi-asserted-by":"publisher","first-page":"e2142078","DOI":"10.1001\/jamanetworkopen.2021.42078","volume":"5","author":"M Bhattarai","year":"2022","unstructured":"Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, et al. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA Netw Open. 2022;5:e2142078.","journal-title":"JAMA Netw Open"},{"key":"2029_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1074248420987054","volume":"26","author":"JL Anderson","year":"2021","unstructured":"Anderson JL, Knowlton KU, Muhlestein JB, Bair TL, Le VT, Horne BD. Evaluation of treatment with angiotensin converting enzyme inhibitors and the risk of lung cancer: ERACER\u2014an observational cohort study. J Cardiovasc Pharm Ther. 2021;26:321\u20137.","journal-title":"J Cardiovasc Pharm Ther"},{"key":"2029_CR24","doi-asserted-by":"publisher","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","volume":"7","author":"L Azoulay","year":"2012","unstructured":"Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS ONE. 2012;7:e50893.","journal-title":"PLoS ONE"},{"key":"2029_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","volume":"74","author":"J Hallas","year":"2012","unstructured":"Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L. Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharm. 2012;74:180\u20138.","journal-title":"Br J Clin Pharm"},{"key":"2029_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.14423\/SMJ.0000000000001293","volume":"114","author":"SA Helgeson","year":"2021","unstructured":"Helgeson SA, Waddle MR, Burnside RC, Debella YT, Lee AS, Burger CD, et al. Association between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and lung cancer. South Med J. 2021;114:607\u201313.","journal-title":"South Med J"},{"key":"2029_CR27","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/jch.14187","volume":"23","author":"MH Jung","year":"2021","unstructured":"Jung MH, Lee JH, Lee CJ, Shin JH, Kang SH, Kwon CH, et al. Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in Korea. J Clin Hypertens. 2021;23:879\u201387.","journal-title":"J Clin Hypertens"},{"key":"2029_CR28","first-page":"e14788","volume":"13","author":"P Kumar","year":"2021","unstructured":"Kumar P, Kumar V, Murlidhar F, Fatima A, Jahangir M, Khalid D, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for incidence of lung cancer: a retrospective study. Cureus. 2021;13:e14788.","journal-title":"Cureus"},{"key":"2029_CR29","doi-asserted-by":"publisher","first-page":"594043","DOI":"10.3389\/fmed.2021.594043","volume":"8","author":"L Meng","year":"2021","unstructured":"Meng L, Yang B, Qiu F, Jia Y, Sun S, Yang J, et al. Lung cancer adverse events reports for angiotensin-converting enzyme inhibitors: data mining of the FDA adverse event reporting system database. Front Med. 2021;8:594043.","journal-title":"Front Med"},{"key":"2029_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","volume":"123","author":"B Pasternak","year":"2011","unstructured":"Pasternak B, Svanstr\u00f6m H, Callr\u00e9us T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123:1729\u201336.","journal-title":"Circulation"},{"key":"2029_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255\u20139.","journal-title":"Lancet"},{"key":"2029_CR32","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","volume":"7","author":"AK Ganti","year":"2021","unstructured":"Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7:1824\u201332.","journal-title":"JAMA Oncol"},{"key":"2029_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1\u20139.","journal-title":"J Natl Cancer Cent"},{"key":"2029_CR34","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jtho.2021.01.1626","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Luo G, Etxeberria J, Hao Y. Global patterns and trends in lung cancer incidence: a population-based study. J Thorac Oncol. 2021;16:933\u201344.","journal-title":"J Thorac Oncol"},{"key":"2029_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12:65\u201382.","journal-title":"Lancet Oncol"},{"key":"2029_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/jcph.1786","volume":"61","author":"M Fernandez-Rando","year":"2021","unstructured":"Fernandez-Rando M, Herrera MD, Almeida-Gonz\u00e1lez CV, Grilo A. Days needed for the disappearance of a cough due to the use of an angiotensin-converting enzyme inhibitor and identification of predisposing factors associated with its appearance in a clinical cohort of hypertensive patients. J Clin Pharm. 2021;61:591\u20137.","journal-title":"J Clin Pharm"},{"key":"2029_CR37","doi-asserted-by":"publisher","first-page":"R205","DOI":"10.1152\/ajpregu.00544.2012","volume":"305","author":"D Okwan-Duodu","year":"2013","unstructured":"Okwan-Duodu D, Landry J, Shen XZ, Diaz R. Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2013;305:R205\u2013215.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2029_CR38","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cancers13112734","volume":"13","author":"GE Riddiough","year":"2021","unstructured":"Riddiough GE, Fifis T, Walsh KA, Muralidharan V, Christophi C, Tran BM, et al. Captopril, a renin-angiotensin system inhibitor, attenuates features of tumor invasion and down-regulates C-Myc expression in a mouse model of colorectal cancer liver metastasis. Cancers. 2021;13:2734.","journal-title":"Cancers"},{"key":"2029_CR39","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","volume":"92","author":"S Friis","year":"2001","unstructured":"Friis S, S\u00f8rensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92:2462\u201370.","journal-title":"Cancer"},{"key":"2029_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","volume":"29","author":"Collaboration, A. T.","year":"2011","unstructured":"Collaboration, A. T. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623\u201335.","journal-title":"J Hypertens"},{"key":"2029_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12094-020-02488-3","volume":"23","author":"B Afsar","year":"2021","unstructured":"Afsar B, Afsar RE, Ertuglu LA, Kuwabara M, Ortiz A, Covic A, et al. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics. Clin Transl Oncol. 2021;23:682\u201396.","journal-title":"Clin Transl Oncol"},{"key":"2029_CR42","first-page":"884","volume":"11","author":"J Yang","year":"2021","unstructured":"Yang J, Yang X, Gao L, Zhang J, Yi C, Huang Y. The role of the renin-angiotensin system inhibitors in malignancy: a review. Am J Cancer Res. 2021;11:884\u201397.","journal-title":"Am J Cancer Res"},{"key":"2029_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jtho.2020.08.021","volume":"16","author":"J Kang","year":"2021","unstructured":"Kang J, Jeong SM, Shin DW, Cho M, Cho JH, Kim J. The associations of aspirin, statins, and metformin with lung cancer risk and related mortality: a time-dependent analysis of population-based nationally representative data. J Thorac Oncol. 2021;16:76\u201388.","journal-title":"J Thorac Oncol"},{"key":"2029_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.106.650176","volume":"115","author":"S Setoguchi","year":"2007","unstructured":"Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115:27\u201333.","journal-title":"Circulation"},{"key":"2029_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1940-6207.CAPR-19-0211","volume":"12","author":"T Zhang","year":"2019","unstructured":"Zhang T, Bai R, Wang Q, Wang K, Li X, Liu K, et al. Fluvastatin inhibits HMG-CoA reductase and prevents non-small cell lung carcinogenesis. Cancer Prev Res. 2019;12:837\u201348.","journal-title":"Cancer Prev Res"},{"key":"2029_CR46","doi-asserted-by":"crossref","unstructured":"Wang CH, Huang CW, Nguyen PA, Lin MC, Yeh CY, Islam MM, et al. Chemopreventive effects of concomitant or individual use of statins, aspirin, metformin, and angiotensin drugs: a study using claims data of 23 million individuals. Cancers. 2022;14:1211.","DOI":"10.3390\/cancers14051211"},{"key":"2029_CR47","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/jpm11111226","volume":"11","author":"TJ O\u2019Brien","year":"2021","unstructured":"O\u2019Brien TJ, Fenton K, Sidahmed A, Barbour A, Harralson AF. Race and drug toxicity: a study of three cardiovascular drugs with strong pharmacogenetic recommendations. J Pers Med. 2021;11:1226.","journal-title":"J Pers Med"},{"key":"2029_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3109\/15376516.2011.623331","volume":"22","author":"W Yusof","year":"2012","unstructured":"Yusof W, Hua GS. Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians. Toxicol Mech Methods. 2012;22:184\u201392.","journal-title":"Toxicol Mech Methods"},{"key":"2029_CR49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11906-020-01101-w","volume":"22","author":"D Patoulias","year":"2020","unstructured":"Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: a Systematic review and meta-analysis. evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22:90.","journal-title":"Curr Hypertens Rep."},{"key":"2029_CR50","first-page":"489","volume":"114","author":"J Hahn","year":"2017","unstructured":"Hahn J, Hoffmann TK, Bock B, Nordmann-Kleiner M, Trainotti S, Greve J. Angioedema. Dtsch Arztebl Int. 2017;114:489\u201396.","journal-title":"Dtsch Arztebl Int"},{"key":"2029_CR51","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jaci.2018.06.037","volume":"142","author":"SA Hubers","year":"2018","unstructured":"Hubers SA, Kohm K, Wei S, Yu C, Nian H, Grabert R, et al. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2018;142:1636\u20131639.e1635.","journal-title":"J Allergy Clin Immunol"},{"key":"2029_CR52","doi-asserted-by":"publisher","first-page":"105020","DOI":"10.1016\/j.neuint.2021.105020","volume":"146","author":"JG Choi","year":"2021","unstructured":"Choi JG, Choi SR, Kang DW, Kim J, Park JB, Kim HW. Inhibition of angiotensin converting enzyme induces mechanical allodynia through increasing substance P expression in mice. Neurochem Int. 2021;146:105020.","journal-title":"Neurochem Int"},{"key":"2029_CR53","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","volume":"46","author":"M Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz M, Cove\u00f1as R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46:1727\u201350.","journal-title":"Amino Acids"},{"key":"2029_CR54","first-page":"3621","volume":"51","author":"T Sethi","year":"1991","unstructured":"Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res. 1991;51:3621\u20133.","journal-title":"Cancer Res"},{"key":"2029_CR55","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1083\/jcb.200802081","volume":"181","author":"OT Fackler","year":"2008","unstructured":"Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol. 2008;181:879\u201384.","journal-title":"J Cell Biol"},{"key":"2029_CR56","first-page":"Cd008170","volume":"11","author":"YJ Chen","year":"2018","unstructured":"Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018;11:Cd008170.","journal-title":"Cochrane Database Syst Rev"},{"key":"2029_CR57","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99:559\u201369.","journal-title":"Kidney Int"},{"key":"2029_CR58","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","volume":"138","author":"F Zannad","year":"2018","unstructured":"Zannad F, Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018;138:929\u201344.","journal-title":"Circulation"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02029-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T18:07:30Z","timestamp":1675879650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-02029-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,19]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-02029-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}